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Background-—Apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio and lipoprotein(a) (Lp[a]) are associated with aortic valve
stenosis (AVS) disease progression. Clinical characteristics such as age, sex, and presence of concomitant coronary artery disease
may strongly modify these associations; however, these effects have not been well deﬁned in longitudinal studies. We set out to
assess these associations between apoB/apoA-I ratio, Lp(a), and AVS incidence in a large population study.
Methods and Results-—We analyzed data from 17 745 participants (mean age, 59.29.1 years; men, 44.9%) in the EPIC-Norfolk
(European Prospective Investigation Into Cancer in Norfolk Prospective Population Study) population study in whom apoB/apoA-I
and Lp(a) levels were measured. Participants were identiﬁed as having incident AVS if they were hospitalized or died with AVS as an
underlying cause. After a median follow-up of 19.8 years (17.9–21.0 years) there were 403 (2.2%) incident cases of AVS. The
hazard ratio for AVS risk was 1.30 (95% CI, 1.19–1.41; P<0.001) per SD increase in apoB/apoA-I. Adjusting for age, sex, and
coronary artery disease, there was no signiﬁcant association between apoB/apoA-I and AVS incidence (hazard ratio, 1.06; 95% CI,
0.97–1.17 [P=0.215]). Elevated Lp(a) (>50 mg/dL) remained an independent risk factor for AVS after adjustment for age, sex, low-
density lipoprotein cholesterol, and concomitant coronary artery disease (hazard ratio, 1.70; 95% CI, 1.33–2.19 [P<0.001]).
Conclusions-—In this population study, apoB/apoA-I ratio was associated with risk of AVS incidence, especially in younger and
female participants and those without concomitant coronary artery disease. Lp(a) was an independent risk factor for AVS
incidence. Interventional trials are needed to investigate whether modulating apoB/apoA-I or lowering Lp(a) can prevent or slow
down AVS. ( J Am Heart Assoc. 2019;8:e013020. DOI: 10.1161/JAHA.119.013020.)
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A therogenic apolipoprotein B (apoB)–containing lipopro-teins such as low-density lipoprotein (LDL) and lipoprotein
(a) (Lp[a]) have clearly been implicated in the pathogenesis of
aortic valve stenosis (AVS).1,2However, trials aimed at reducing
LDL cholesterol (LDL-C) with statins and ezetimibe have failed
to document a signiﬁcant reduction in AVS progression3 and Lp
(a)-targeted trials have yet to be performed, currently leaving
clinicians with no proven medical therapy to reduce disease
progression.
A recent Swedish case-control study reported that apoB/
apolipoprotein A-I (apoA-I) ratio and Lp(a) were associated
with future AVS surgery in patients with concomitant coronary
artery disease (CAD) but not in those with “isolated” AVS.4
These ﬁndings suggested that patients with AVS could have
different phenotypes, in which risk factors such as athero-
genic lipoproteins may or may not play a major role in driving
disease progression. In addition, post hoc analyses of the
PROGRESSA (Metabolic Determinants of the Progression of
Aortic Stenosis) trial5 found that apoB/apoA-I was associated
with faster hemodynamic progression in patients with mild
to moderate AVS. These effects appeared especially pro-
nounced in the younger subset of patients, suggesting that
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lipoprotein-mediated pathology is dominant in younger patients,
while other risk factors may contribute more to disease
progression in elderly patients.
Risk factors for AVS progression can differ from those
associated with AVS incidence as a result of underlying
differences in pathophysiology in the initiation and propaga-
tion stages of disease.6 Large longitudinal cohorts are needed
to assess whether and in whom these risk factors could be
viable for intervention or risk stratiﬁcation. It is unknown
whether apoB/apoA-I ratio is associated with AVS incidence
in the general population. Whether the associations between
apoB/apoA-I ratio, Lp(a), and AVS incidence are independent
of presence of CAD is also unknown.
The goal of this study was 2-fold: (1) to assess the
associations between apoB/apoA-I ratio, Lp(a), and AVS
incidence in a prospective, longitudinal study, and (2) to
evaluate how clinical characteristics modify these associa-
tions. These data could have important implications for the
design of future randomized trials to evaluate novel lipid-
lowering therapies, as well for individual risk assessment or
treatment of patients with AVS.
Methods
EPIC-Norfolk (European Prospective Investigation Into Cancer
in Norfolk Prospective Population Study) data will not be
made publicly available for purposes of reproducing the
results. Procedures to request access to EPIC-Norfolk data
can be found online (http://www.srl.cam.ac.uk/epic/).
EPIC-Norfolk Population Study
The EPIC-Norfolk was a prospective population study of 25 639
male and female inhabitants of Norfolk, United Kingdom, aged
between 39 and 79 years. The design and methods of EPIC-
Norfolk have been previously described in detail.7 Data were
collected from February 1993 through March 2016. The
primary outcome was AVS. Participants were identiﬁed as
having incident AVS if they were hospitalized with AVS
(International Classiﬁcation of Diseases, Tenth Revision [ICD-
10] code I35) as an underlying cause or if they died with AVS as
an underlying cause. We deﬁned the presence of concomitant
CAD as self-reporting a history of prevalent CAD at baseline or
ﬁrst incident CAD during follow-up (ICD-10 code I20–25). The
Norwich District Health Authority Ethics Committee approved
the study, and all participants gave signed informed consent.
Laboratory Measurements
Conventional lipid proﬁles were measured at baseline as
previously described.7 LDL-C was calculated using the
Friedewald formula. ApoB and apoA-I were measured using
rate immunonephelometry (Behring Nephelometer BNII). Lp(a)
levels were measured in baseline samples (stored frozen at
80°C for 15 years) with an immunoturbidimetric assay
using polyclonocal antibodies directed against epitopes in
apolipoprotein(a) (Denka Seiken) as previously described.8
Statistical Analyses
For this prospective analysis, study participants were
excluded if apoB, apoA-I, or Lp(a) levels were missing.
Baseline characteristics and lipid measurements were com-
pared between participants who developed AVS during follow-
up versus those who did not with the unpaired Student t test.
Cox regression analysis was used to calculate hazard ratios
(HRs) and corresponding 95% CIs for the time to hospitaliza-
tion or death because of AVS. Statistical analyses were
performed using SPSS software version 25 (SPSS Inc).
Results
Complete data were available in 17 745 participants (mean
age 59.29.1 years; male 44.9%) (Table). At baseline, 579
participants reported a history of CAD and 3300 participants
had a ﬁrst incident event of CAD during follow-up. After a
median follow-up of 19.8 years (17.9–21.0 years), there were
403 (2.2%) incident cases of AVS. The associations between
apoB/apoA-I, Lp(a), and risk of incident AVS are shown in
Figure.
The mean apoB/apoA-I ratio was higher among cases than
among controls (0.700.19 versus 0.640.19; P<0.001). In
the entire study cohort, the HR for AVS risk was 1.30 (95% CI,
Table. Baseline Characteristics
Variable Controls Cases P Value
No. (%) 17 342 (97.8) 403 (2.2)
Age, y 59.19.1 64.97.2 <0.001
Men, % 44.7 52.1 0.003
Body mass
index, kg/m2
26.23.8 27.33.8 <0.001
Concomitant CAD, % 20.9 63.5 <0.001
LDL-C, mg/dL 14739 15942 <0.001
apoA-I, mg/dL 15632 15632 0.99
apoB, mg/dL 9724 10525 <0.001
apoB/apoA-I ratio 0.640.19 0.700.19 <0.001
Lp(a), mg/dL 11.7 (6.3–27.7) 15.3 (7.0–41.7) <0.001
Data are presented as meanSD or median (interquartile range) unless otherwise
indicated. Low-density lipoprotein cholesterol (LDL-C) was corrected for cholesterol
content in lipoprotein(a) (Lp[a]): LDL-C=LDL-CLp(a) mass90.3. ApoA-I indicates
apolipoprotein A-I; apoB, apolipoprotein B; CAD, coronary artery disease.
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1.19–1.41) per SD increase in apoB/apoA-I. After adjusting
for age and sex, this relationship was attenuated (HR, 1.18;
95% CI, 1.07–1.30 [P=0.001]). Notably, after additional
adjustment for concomitant CAD, there was no signiﬁcant
association between apoB/apoA-I and AVS incidence (HR,
1.06; 95% CI, 0.97–1.17 [P=0.215]). The risk of AVS stratiﬁed
per apoB/apoA-I quartile is documented in Figure S1.
We further investigated these ﬁndings by analyzing apoB/
apoA-I ratio and stratifying by age, sex, or concomitant CAD.
In younger participants (median age, ≤59 years) the HR for
AVS risk was 1.28 (95% CI, 1.05–1.56; P=0.014) for each SD
increase in apoB/apoA-I, whereas this appeared slightly lower
in older participants (>59 years; HR, 1.20 [95% CI, 1.08–
1.33]; P=0.001). In even older participants (>67 years, top
Figure. Risk of aortic valve stenosis (AVS) incidence associated with apolipoprotein B/apolipoprotein A-I
(apoB/apoA-I) and lipoprotein(a) (Lp[a]). Multivariate Cox proportional hazards analysis for AVS incidence.
CAD indicates concomitant coronary artery disease.
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quartile), the apoB/apoA-I ratio was not associated with AVS
risk (HR, 1.03; 95% CI, 0.88–1.20 [P=0.74]). Comparing
sexes, we found a stronger association for apoB/apoA-I ratio
and AVS risk in women (HR, 1.39; 95% CI, 1.23–1.58
[P<0.001]) compared with men (HR, 1.16; 95% CI, 1.02–1.32
[P=0.025]). Stratifying for CAD, we found that apoB/apoA-I
ratio was associated with a higher risk in patients without
concomitant CAD (HR, 1.20; 95% CI, 1.02–1.40 [P=0.025]),
compared with participants with CAD (HR, 1.02; 95% CI,
0.91–1.14 [P=0.78]). These ﬁndings were further supported
when we tested apoB/apoA-I for interactions with age older
than 67 years (P=0.001), sex (P=0.045), and concomitant
CAD (P=0.075). Age as a continuous variable did not reach
statistical signiﬁcance as an interaction term (P=0.190).
In secondary analyses, we corrected apoB for its contri-
bution in Lp(a). The associations between corrected apoB/
apoA-I and AVS incidence were slightly attenuated compared
with uncorrected apoB/apoA-I, but overall results were similar
(Table S1, Figure S2).
Previously, we reported the independent associations
between elevated levels of Lp(a) (≥50 mg/dL) and risk of
incident AVS, after adjustment for age, sex, and LDL-C.9
Additional adjustment for concomitant CAD did not markedly
impact this relationship (HR, 1.99; 95% CI, 1.55–2.56
[P<0.001] versus CAD adjusted HR, 1.70; 95% CI, 1.33–
2.19 [P<0.001]). Stratiﬁcation by quartiles revealed that the
risk for AVS clearly begins to increase in the top quartile
(≥28 mg/dL) (Figure S1). The HRs per each unit increase of
natural log-transformed Lp(a) levels, stratiﬁed by the presence
of concomitant CAD were also similar (no CAD HR, 1.17; 95%
CI, 0.99–1.38 [P=0.06] versus CAD HR, 1.19; 95% CI, 1.05–
1.34 [P=0.006]).
Elevated Lp(a) has been suggested to synergistically
increase CAD risk in patients with elevated LDL-C.10 To
investigate this concept for AVS risk, we stratiﬁed for elevated
LDL-C and compared the HRs per each unit increase of natural-
log transformed Lp(a) (Table S2). Lp(a) levels appeared to
confer more risk in patients with elevated LDL-C between
160 mg/dL and 190 mg/dL (HR, 1.56; 95% CI, 1.29–1.90
[P<0.001]) compared with patients with LDL-C <160 mg/dL
(HR, 1.22; 95% CI, 1.06–1.40 [P=0.006]). However, this was
not the case in patients with even higher LDL-C ≥190 mg/dL
(HR, 1.178; 95% CI, 0.940–1.477 [P=0.154]). We did not ﬁnd a
statistical signiﬁcant interaction between corrected apoB/
apoA-I ratio and natural log-transformed Lp(a) levels (P=0.916).
Discussion
The apoB/apoA-I ratio is considered to reﬂect the balance
between atherogenic apoB-containing particles and
antiatherogenic high-density lipoprotein particles.11 As such,
this metric captures both dyslipidemia and dysmetabolic
regulation. In our population study, apoB/apoA-I ratio was
found to be a strong predictor of AVS incidence, especially in
younger and female participants. These ﬁndings support the
concept that lipoproteins are involved in the pathogenesis of
AVS, and are also compatible with the failure of previous
statin trials to reduce AVS progression by LDL-C lowering.
Because these trials included mostly older (and male) patients
with AVS, disease may have been too advanced to be
amenable to lipid-lowering therapy, suggesting that LDL or
apoB-containing particles play a predominant role in early
stages of disease but are less important with increasing
disease severity. Our observation that apoB/apoA-I ratio was
a stronger risk predictor in women compared with men is in
line with emerging clinical data on sex-related differences in
AVS pathogenesis.12 Recent studies showed that women
needed less valvular calcium burden than men to develop
severe AVS,13 while women also demonstrated differential left
ventricular remodeling and earlier symptom onset in AVS
compared with men.14 Collectively, these data highlight the
need for further studies to advance our understanding of sex
differences in AVS pathogenesis to ultimately improve clinical
management.
In contrast to an earlier report by Ljungberg and
colleagues,4 we found that the apoB/apoA-I ratio–associated
risk of AVS incidence was higher in participants without
concomitant CAD compared with those with CAD. Consider-
ing AVS shares many other risk factors with atherosclerosis,
participants with CAD may also already have established
subclinical AVS, at which stage increased apoB/apoA-I may
not confer any additional risk for AVS incidence. Interestingly,
Lp(a) levels persisted as a risk factor in nearly all tested
subgroups—including patients with concomitant CAD—sug-
gesting that perhaps the oxidized phospholipids or other
moiety on the Lp(a) particle act via different pathways than
other apoB-containing lipoproteins. These ﬁndings are in line
with a recent multimodality imaging study in which elevated
Lp(a) and oxidized phospholipids on apoB were associated
with faster disease progression independent of concomitant
CAD.15 Furthermore, a secondary analysis of the ASTRON-
OMER (Aortic Stenosis Progression Observation: Measuring
Effects of Rosuvastatin) study,16 which excluded patients with
concomitant CAD, demonstrated that elevated Lp(a) and
oxidized phospholipids on apoB were associated with faster
hemodynamic progression and need for valve replacement. In
the setting of elevated LDL-C, Lp(a) was associated with an
additional risk of AVS incidence, although this was not clear in
patients with severe hypercholesterolemia (LDL-C ≥190 mg/
dL). This group likely includes patients with a familial
hypercholesterolemia phenotype, in whom AVS risk is
increased such that the contribution of Lp(a) is relatively
small, or perhaps that patients die of atherosclerotic disease
before any AVS diagnosis can be made.
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Clinical trials investigating novel therapies are needed to
determine whether modulating the apoB/apoA-I ratio or
lowering Lp(a) can prevent or slow disease progress in AVS.
Previous clinical studies have established that PCSK9
inhibitors are able to reduce both LDL-C and Lp(a).17 In
addition, the PCSK9 R46L loss-of-function mutation is asso-
ciated with reduced risk of AVS and myocardial infarction.18
Recently, experimental data suggested that PCSK9 may also
directly facilitate calciﬁcation in valvular interstitial cells.19
Taken together, PCSK9 inhibition therapy could potentially
reduce AVS disease progression and valve-related events. To
our knowledge, only 1 clinical trial is currently registered that
aims to test this hypothesis (NCT03051360). Antisense
oligonucleotides against apolipoprotein(a) have been demon-
strated to effectively reduce Lp(a) levels,20 and a phase III
cardiovascular outcomes trial is being planned. A dedicated
antisense trial will be needed to test the Lp(a) hypothesis in
patients with AVS.
Study Limitations
Our study is observational and limited by deﬁning AVS
outcome based on ICD-10–coded hospitalizations and mor-
tality. In this respect, the diagnosis of AVS was not
standardized. However, a large medical records study has
recently reported that this ICD-10 approach resulted in high
diagnostic accuracy (>90%) in Sweden,21 but also restricted
outcome to moderate to severe AVS cases.
Conclusions
In the EPIC-Norfolk population study, apoB/apoA-I ratio was
associated with risk of AVS incidence, especially in younger
and female participants and those without concomitant CAD.
Lp(a) was an independent risk factor for AVS incidence.
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Table S1. Baseline apoB value corrected for its contribution in Lp(a). 
Variable Controls Cases p-value 
Secondary analyses    
apoB corrected for Lp(a) mass 94 ± 24 101 ± 25 <0.001 
apoBcorr. for Lp(a) mass/apoA-I  ratio 0.62 ± 0.18 0.67 ± 0.19 <0.001 
 
ApoB was corrected for its contribution in Lp(a) using the following calculation: apoB 
corrected for Lp(a) mass = apoB–(Lp(a)mass*0.16]).1 
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Table S2. Risk of aortic valve stenosis associated with natural log-transformed Lp(a) 
stratified by LDL-c levels. 
LDL-c group 
(mg/dL) 
Unadj. HR (95% CI) HR adj. for age and 
sex (95% CI) 
HR adj. for age, sex 
and CAD (95% CI) 
LDL-c < 160 1.217 (1.058-1.399); 
p=0.006 
1.189 (1.031-1.379); 
p=0.017 
1.131 (0.983-1.300); 
p=0.085 
160 ≥ LDL-c < 190  1.564 (1.289-1.898); 
p<0.001 
1.569 (1.284-1.916); 
p<0.001 
1.444 (1.184-1.762); 
p<0.001 
LDL-c ≥ 190 1.178 (0.940-1.477); 
p=0.154 
1.130 (0.901-1.416); 
p=0.290 
1.090 (0.870-1.365); 
p=0.453 
 
HR = Hazard ratio per unit increase of natural log-transformed Lp(a) levels. 
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Figure S1. Risk of aortic valve stenosis incidence associated with quartiles of 
apoB/apoA-I ratio and Lp(a). 
 
Multivariate Cox proportional hazards analysis for AVS incidence. Q = quartile; LDL-c = 
low-density lipoprotein cholesterol; CAD = concomitant coronary artery disease. 
D
ow
nloaded from
 http://ahajournals.org by on August 16, 2019
Figure S2. Risk of aortic valve stenosis incidence associated with corrected apoB/apoA-I. 
 
Multivariate Cox proportional hazards analysis for AVS incidence. CAD = concomitant 
coronary artery disease; SD = standard deviation. 
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